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The burden of liver cancer is higher in Hispanics, African Americans, and 
Asians. Viral hepatitis (Hepatitis B and Hepatitis C viruses), non-alcoholic ste-
atohepatitis (NASH), and alcoholic liver disease (ALD) are the most common 
etiological/risk factors for liver cancer. Approximately 80–90% of hepatocellular 
carcinoma (HCC) occurs in patients with underlying liver cirrhosis. Individuals 
with advanced cirrhosis represent a high-risk group for liver cancer. To fill the 
increasing gap between basic science and clinical research, translational research 
has been developed as an emerging technology. Basic science attempts to unravel 
the mechanisms of disease using tools (e.g., culture systems and animal models) 
that allow for easy manipulation of biological processes. Further, culture systems 
and animal models are useful to derive causal associations, but they generally do 
not include an endpoint directly applicable to clinical practice. Hence, develop-
ment of new tools for early detection, including the evaluation of liquid biopsy, 
identification of tissue biomarkers of treatment response, execution of precision 
and enhancement of patient stratification in patients at risk for HCC development 
to enable chemoprevention clinical trials becomes important. It was identified as 
translational research has begun as an effective approach to facilitate the develop-
ment of novel molecular-based biomarkers and to accelerate the implementation of 
laboratory discoveries into clinically applicable tools. Despite great advancement in 
diagnosis and management of HCC, the exact biology of the tumor remains poorly 
understood generally limiting the clinical outcome. Comprehensive analysis and 
characterization of the molecular mechanisms and subsequently individual predic-
tion of corresponding prognostic traits would transform both diagnosis and treat-
ment of HCC and is the key goal of modern medicine. To overcome the challenge 
and to accelerate the progress, a collaborative effort from various clinical research 
groups and translational approach is needed.
Keywords: biomarkers, clinical research, cancer, hepatocellular carcinoma and 
translational research
1. Introduction
Hepatocellular carcinoma (HCC) is a common form of liver cancer associated 
with high mortality rate [1]. It is estimated that approximately 750,000 new cases 
of HCC diagnosed per year worldwide which makes HCC as the fifth common cause 
of cancers affecting human [2]. Mortality rate of approximately 700,000 has been 
estimated annually due to HCC and it has been considered as the third common 
cause of death [3].
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World Health Organization (WHO) reported that about one million people 
annually was diagnosed with HCC [4]. The major risk factors for developing 
HCC are viral infections, alcoholic liver diseases and nonalcoholic steatohepatitis 
(NASH) [5]. In most of the cases, HCC was diagnosed after the disease progresses, 
when survival rates are low [6]. Development of HCC is asymptomatic at early 
stages of the disease when current curative therapies are available [7]. Diagnosis of 
HCC is based on the combination of radiological, serological and histopathological 
criteria [8]. Almost 90% of the cases are diagnosed without the help of liver biopsy, 
as many non-invasive techniques such as serological examination and imaging 
techniques are used as standard diagnostic test for HCC [9]. Ultrasonography is 
the most widely used imaging test for screening because of its diagnostic accuracy, 
non-invasiveness, good acceptance by patients and moderate cost [10].
Because of a large variability in etiological and genetic backgrounds and the 
long-time development of the disease, HCC lesions are known to exhibit substantial 
intra-tumor and inter-tumor heterogeneity [11]. For the treatment stratification in 
HCC, tumor heterogeneity poses a significant challenge [12]. Non-invasive assess-
ment of several tumor characteristics, such as cellularity, perfusion and oxygen-
ation, can be performed using quantitative functional multiparametric magnetic 
resonance imaging (mpMRI), which can be also used for tumor characterization 
and for assessing the treatment response [13]. Although pathological and genetic 
heterogeneity in HCC lesions have been defined, imaging reports on HCC hetero-
geneity are extremely inadequate, with only one study reporting visual assessment 
of HCC heterogeneity on contrast-enhanced MRI, with no such study describing 
quantitative imaging measurements of HCC heterogeneity [14].
Nowadays, magnetic resonance imaging (MRI) analysis has been used to study 
the characterization of HCC lesions in biopsied or resected samples, and also it 
provides further information on tumor properties [15]. Without histological con-
firmation, HCC can be detected using imaging alone in most of the patients, [16], 
but histopathologic assessment has its own advantage over imaging analysis. Results 
of the study by Hectors et al. indicated that HCC patients could ultimately benefit 
from knowledge of about the correlation of imaging parameters with histopatho-
logical and genomics properties of HCC lesions [17].
Based on tumor burden, hepatic function and performance status, patient 
prognosis and treatment decisions are made [18]. Surgical resection and liver 
transplantation are generally recommended for HCC, but is indicated specifically 
for patients with early stage and well-preserved liver function [19]. For patients not 
suitable for curative treatment, transarterial chemoembolization (TACE) and trans-
arterial radioembolization (TARE) may provide better loco-regional tumor control 
and increase patient survival [20]. It is commonly acknowledged as a palliative 
treatment option and improves survival in unresectable HCC.
Primary liver cancer or HCC imposes significant challenges to healthcare with 
huge unmet clinical needs. In males, it is the second leading cause of cancer-related 
mortality worldwide and 80% of HCC cases are found in the Asia-Pacific regions 
[21]. Although treatments such as surgical resection, liver transplantation or radio-
frequency ablation are potentially curable options for early-stage HCC, recurrences 
remain the most common issue and limit the overall survival [22]. Survival may 
be prolonged by loco-regional therapy in intermediate stage HCC and by systemic 
therapies in advanced HCC [23]. Overall, when compared to other common can-
cers, clinical outcomes in HCC remain poor due to the lack of effective therapies 
[24]. It’s intrinsically quite challenging to understand the biology of HCC as it is the 
common end-point of a number of etiologies with different molecular pathways. 
In addition to increasing the complexity, significant heterogeneity is also existent 
within the same tumor [25].
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Treatment outcomes for the majority of patients with HCC have remained poor 
through the years. The overall 5-year survival rate for all patients with HCC has 
remained steady at 3–5% [26]. This results from two facts. The first major reason is 
that for most patients, diagnosis is made only when the disease is in advanced stage 
and inoperable, and the second reason is when the disease has very poor prognosis. 
Furthermore, cirrhosis of the liver is a major risk factor for HCC development [27]. 
In most of the cases, the cause of cirrhosis is mainly due to chronic hepatitis B or C 
virus infection, or heavy alcohol usage [28]. Other known risk factors may include 
hereditary hemochromatosis, α-1 antitrypsin deficiency, primary biliary cirrhosis, 
autoimmune hepatitis, smoking and aflatoxin exposure [29]. Regardless of the 
cause, the accompanying cirrhosis can independently cause death as well as compli-
cate other treatments [30].
Because of the challenges faced by current and future populations due to HCC, 
treatment has been an ever-rising area of interest for research. So far there was no 
such improved results from cytotoxic therapies have been reported. Researchers’ 
recent efforts have been mainly focused on a variety of proven tactics and techniques 
[30]. Reducing morbidity and mortality are the major concerns in the modern surgi-
cal era, as various studies have recommended that precise evaluation of liver func-
tion reserve is indispensable for prognosticating the occurrence of morbidities and 
mortalities [31]. A number of confounding variables and background liver changes 
pose a major challenge in clinical proteomics studies that target liver diseases and 
biomarker discovery. Fat accumulation, inflammation, necrosis, apoptosis, prolifera-
tion, fibrosis and viral replication can all occur simultaneously in liver injury [32]. In 
general, insulin resistance is associated with the pathogenesis of nonalcoholic fatty 
liver disease (NAFLD). A role of hepatic steatosis in the pathogenesis of chronic 
hepatitis C has also been studied, implying hepatitis C as a metabolic disease. As a 
result, there is a need for novel strategies and careful experimental design [32].
To improve our better understanding of the liver biology, integrative studies 
such as proteomics and basic cellular biology or other developing fields such as 
imaging studies and mouse models will play the most prominent role. The transla-
tion of basic discoveries into daily clinical practice will accelerate the ability to 
understand the underlying molecular dysfunction in human disease (such as 
signaling pathways, protein–protein interaction networks) [32]. A study by Li et al. 
showed how mouse models of liver disease can be used to provide valuable func-
tional information. Therefore, it helps to improve the current concepts for better 
screening and prevention [33]. Conde-Vandellis et al., described that biomarker 
discovery revealed a powerful new path to study proteomic analysis of extracellular, 
circulating or urinary vesicles [34].
2. Biomarkers in HCC
Various circulating markers and tissue markers have been identified. Because 
of their low predictive accuracy and/or high cost, few biomarkers are acceptable 
for clinical utility [35]. Alpha-fetoprotein (AFP) was the first serologic assay for 
the detection and clinical follow-up of patients with HCC, which has been the 
standard tumor biomarker for HCC for many years [36]. Analysis of recent studies 
has indicated that AFP testing lacks adequate sensitivity and specificity for effective 
surveillance [37]. AFP levels were reported to be normal in up to 40% of patients 
with HCC, particularly during the early stage of the disease [38]. The combina-
tional use of different biomarkers may enhance the detection sensitivity for the 
early detection of HCC. The tumor markers are most useful if utilized not only as 
confirmatory tests, but also as a part of routine follow-up [39].
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Instead of simply utilizing a tumor marker test during the initial cancer evalua-
tion, following the tumor marker levels serially against the background of clinical 
and other diagnostic findings will enhance the value of the tumor marker in provid-
ing information that could be used in therapeutic decisions and evaluation [39]. In 
recent years, many promising candidate biomarkers for HCC have been identified, 
but most of them have not been applied in the clinical diagnosis due to their limited 
practicability and high cost.
Discovering novel biomarkers that provide sensitive and specific detection of 
early stage disease when it is highly treatable is crucial [40]. In blood, the presence 
of low abundance and low molecular weight proteins and metabolites provide a 
potential and beneficial information, which also have great promise as a source of 
new biomarkers [41]. Unfortunately, they comprise less than 1 percent of the blood 
molecules, and in many cases exist in at two molar concentrations. The remainder 
of the proteins and peptides comprising the complex circulatory proteome range 
from 10 to 12 mg/mL to 10–3 mg/mL, spanning ten orders of magnitude, with a few 
high molecular weight proteins such as albumin and immunoglobulins accounting 
for 90% of total protein content [42].
It is quite difficult to detect and quantify low abundance, low molecular weight 
proteins and metabolites using conventional protein detection methods such as 
two dimensional gel electrophoresis (2-DGE), as they do not have the sensitivity 
and high resolution [43]. As the input volume is only a few microliters, it’s also 
quite challenging for the moderately high-detection and sensitive modern mass 
spectrometers (at to molar concentration). And the complexity of protein mixture 
will influence the sensitivity and resolution [43]. The usual sample preparation 
steps for mass spectrometry (MS) experiments have several steps. MS experiments 
start with the depletion of high abundant proteins using commercially available 
immunoaffinity depletion columns. After depletion process, using size exclusion 
chromatography, ion exchange chromatography and/or isoelectric focusing it has 
been fractionized. However, as it has been recently shown that the vast majority 
of low abundance biomarkers are non-covalently and endogenously associated 
with the carrier proteins that are being removed, removal of abundant native high 
molecular weight proteins can significantly reduce the yield of candidate biomark-
ers [44]. Methods, such as size exclusion ultrafiltration under denaturing condi-
tions, continuous elution denaturing electrophoresis or fractionation of serum by 
means of nano-porous substrates, have been proposed to solve this problem, but 
these methods are very time consuming, [45]. In the past, there has been no routine 
method for purifying and enriching low molecular mass peptides and metabolites 
from complex protein mixtures and biologic fluids in solution [46].
3. Translational research
In hepatology, HCC is an area that could benefit from translational research. In 
advanced-stage HCC, until 2016, sorafenib was the only systemic agent that can 
increase survival in patients [47]. In the meantime, four drugs, which include len-
vatinib, regorafenib, cabozantinib and ramucirumab, have shown clinical efficacy 
either in first- or second-line therapy after phase 3 clinical trials [48]. Response 
rate of 14% for nivolumab and 17% for pembrolizumab was observed and they 
also increased the duration of response more than 1 year in half of the responders 
prompted the US Food and Drug Administration (FDA) approval of these two 
drugs under the accelerated program after single-arm phase 1/2 trials [49].
There are no other biomarkers except AFP that can identify the best responders 
to any other therapies, while the patients receiving ramucirumab in second-line 
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therapy [48]. To identify an immune subclass in HCC resection specimens, trans-
lational research efforts played a prominent role. Its ability to predict response to 
immune-based therapies is still under investigation [50]. This is quite different 
with other tumor types where comprehensive molecular profiling of large sets of 
samples enabled the identification of robust predictive biomarkers of treatment 
response (e.g., BRAF mutations and response to vemurafenib in melanoma, and 
ALK rearrangements and response to crizotinib in lung cancer) [51]. These transla-
tional research initiatives helped coin the concept of “oncogene addiction,” a term 
that describes a selective dependence of cancer cell growth for a certain genetic 
alteration. Some of these biomarkers are included in clinical practice guide-lines 
and FDA label [52].
As translational research established itself as a bridge between basic research 
and clinical practice, its application spread beyond cancer to disease in general and 
then to non-biomedical fields such as engineering [52]. Genome-wide association 
studies have shown that only a small fraction of an individual’s risk for cancer can 
be predicted by their genetic constitution and that hundreds of genetic variants 
conspire to determine that risk [53]. Often, disease-related genetic variants do not 
alter protein-coding regions of the genome, and evidence is emerging to show that 
they influence cell physiology by altering non-coding RNAs with gene regulatory 
roles [54]. Additional layers of complexity have emerged from the sequencing of 
cancer genomes. These efforts have revealed large intra-individual heterogeneity in 
neoplasms of the same organ and histotype, i.e., each tumor has its own mutational 
profile [54]. Additionally, they have uncovered substantial intra-tumoral hetero-
geneity that complicates treatment decisions and calls into question the strategy of 
genotyping tumoral DNA using a single biopsy [55]. Altogether, this new under-
standing of cancer complexity is the driving force in the development of diagnostic 
tests for the molecular profiling of tumors, which may guide the choice of suitable 
personalized therapies for each patient [52].
4. Emerging methods in HCC
The stability of potential biomarkers poses a major challenge is greater over the 
complications associated with the harvest and enrichment of candidate biomarkers 
from complex natural protein mixtures (such as blood) [46]. Immediately after 
blood collection (e.g., by venipuncture), proteins that present in the serum are at 
risk of degradation by endogenous proteases or exogenous environmental prote-
ases, such as proteases associated with the blood clotting process, enzymes shed 
from blood cells or associated with bacterial contaminants [56].
During transportation and storage, there is an increasing chance for the degra-
dation of candidate diagnostic biomarkers in the blood. When the serum and other 
body fluids that are collected from a multiple institutions and different locations as 
large repositories where samples may be shipped without freezing, the fidelity of 
biomarkers becomes an even more important issue [46].
The fundamental and serious physiologic barriers upsetting biomarker discov-
ery and measurement is the extremely low abundance (concentration) of candidate 
markers in blood and urine. Low limits of the biomarkers are very difficult to detect 
by mass spectrometry and conventional immunoassays. And also in the early stage 
of disease, the tissue contains a small proportion of the patient’s tissue volume, thus 
generating a low amount of biomarkers [46].
The resident proteins such as albumin and immunoglobulins are the next 
hindrances, which account for greater than 90% of circulating plasma proteins, as 
it confound and mask the isolation of rare biomarkers. When compared to the rare 
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biomarker, the resident proteins such as albumin exist in billion fold excess. The 
major problem is that the majority of low abundance biomarkers are non-covalently 
and endogenously associated with that resident proteins [46].
After blood or urine collection, the low abundance biomarkers are rapidly 
degraded by endogenous and exogenous proteinases. And also during transporta-
tion and storage of blood, candidate biomarkers are degraded which lead to serious 
false-positive and false-negative results [57].
Affinity bait hydrogel nanoparticles have been recently proposed in order to 
address these fundamental roadblocks to biomarker purification and preserva-
tion [58]. The nanoparticles contain a bait that targets classes of analytes. The 
nanoparticles simultaneously conduct molecular sieve chromatography and affinity 
chromatography, in one step, when it combined with a body fluid such as blood 
or urine [57]. The nanoparticles sequester all target molecules away from albumin 
association and completely exclude albumin [58]. It is proposed that proteins 
sequestered by the nanoparticles are eluted in small volumes, thus increasing their 
concentration, allowing analysis by a variety of techniques, such as mass spectrom-
etry, western blotting and immunoassays [57, 58].
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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